The possibilities of tapentadol in the pharmacotherapy of breakthrough pain in patients with cancer pain and chronic noncancer pain
Abstract
Tapentadol is the latest discovered molecule in a strong opioid group. Tapentadol has a synergistic dual effect (MOR / NRI).
Tapentadol especially excels in low incidence of side effects and have very good sensitivity for neuropathic pain. The advantage of tapentadol is in its availability of both forms in sustained release (SR) and immediately release (IR) form.
In the first case study we demonstrate oncology patient who suffers from chronic neuropathic pain and attacks of short worsening pain. Patient's analgetic medication was partially limited by side effects.
Combined medication of SR and IR form of tapentadol bring the patient benefit of good pain management and absence of side effects. The second case report describes a patient with diabetic neuropathy and the possibility of influencing the component of neuropathic pain, we also combine both forms of tapentadol IR and SR.